Mycograb in Combination with Caspofungin in Murine Models of Candidiasis.

S. HODGETTS 1, L. NOONEY1, S. AWAD 2, R. MATTHEWS 1,2, J. BURNIE 1,2;

Author address: 

1NeuTec Pharma plc, Manchester, United Kingdom, 2Univ. of Manchester, Manchester, United Kingdom.

Abstract: 

Seven Candida strains were evaluated. The strains chosen represent the most clinically significant Candida species; C.albicans (fluconazole resistant (flcr)), C.albicans (fluconazole sensitive (flcs)), C.krusei, C.glabrata, C.tropicalis, C.parapsilosis and C.guilliermondii. The minimum dose of the chosen Candida species was given to produce a sustained infection. Doses of Mycograb (2mg/kg) and caspofungin (ranging from 0 - 4mg/kg) were administered intravenously. Mycograb alone was shown to reduce organ colony counts in most of the species examined. Caspofungin used alone reduced organ fungal load and at a dose of 4mg/kg cleared infections caused by C.albicans flcr. Mycograb and caspofungin in combination improved outcome with all seven strains tested. Mycograb (2mg/kg) plus caspofungin (4mg/kg) sterilised all three organs tested (kidney, liver, spleen) of the C.albicans flcs (Fisher’s exact test p
2006

abstract No: 

M-1751

Full conference title: 

46th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC 46th